Identification of new inhibitors of the Toxoplasma gondii by using in-silico drug repurposing
Kadkhodamohammadi, M.; Jaberi, M.; Babaei Akerdi, R.; Karimi, P.; Ahmadi, A.; Aliyar, M.
Show abstract
IntroductionThe common treatment for toxoplasmosis was pyrimethamine. In recent years, it has been found that this parasite is getting resistant to this treatment, therefore urgent alternative treatments are needed. Material and MethodsIn this study, by using drug repurposing and in silico methods we tried to make a selective treatment by inhibiting the Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii which doesnt exist in mammalians. We screened the FDA approved drugs by molecular docking and after ranking them by their binding energies and inspecting the top scored ones, we chose Cefpiramide, Ceftriaxone and Cefotiam as the hit compounds. After that, we used molecular dynamics simulations to test the hit compounds in a much more realistic environment. ResultsBy analyzing the results, we found that all of the hit compounds and good and can bind strongly to the active site of the protein. Therefore, they can be potential candidates for inhibiting Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii. ConclusionMoreover, because the predicted compounds are FDA approved drugs, their toxicity profiles are well known and their newly predicted use can be tested in clinical trials.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Identification of Natural Antiviral Drug Candidates Against Tilapia Lake Virus: Computational Drug Design Approaches 98%
- Molecular docking, simulation and binding free energy analysis of small molecules as PfHT1 inhibitors 97%
- Antivirals for Monkeypox Virus: Proposing an Effective Machine/Deep Learning Framework 97%
Similar papers in this journal
- An insight into SARS-CoV-2 Membrane protein interaction with Spike, Envelope, and Nucleocapsid proteins 97%
- A program to automate the discovery of drugs for West Nile and Dengue virus -- programmatic screening of over a billion compounds on PubChem, generation of drug leads and automated In Silico modelling 97%
- Investigating the role of N-terminal domain in phosphodiesterase 4B-inhibition by molecular dynamics simulation 97%
Similar papers in this journal
- Machine learning prediction of antiviral-HPV protein interactions for anti-HPV pharmacotherapy 96%
- Mechanistic insights into the deleterious role of nasu-hakola disease associated TREM2 variants 95%
- Mechanistic insights into the Japanese Encephalitis Virus RNA dependent RNA polymerase protein inhibition by bioflavonoids from Azadirachta indica 95%
Similar papers in this journal
- Characterization of the NiRAN domain from RNA-dependent RNA polymerase provides insights into a potential therapeutic target against SARS-CoV-2 95%
- A new machine learning method for cancer mutation analysis 94%
- Protein Domain-Based Prediction of Compound-Target Interactions and Experimental Validation on LIM Kinases 93%
Similar papers in this journal
- Bioinfo-pharmacology: the example of therapeutic hypothermia 97%
- Studying protein-protein interaction through side-chain modeling method OPUS-Mut 96%
- Design of an Epitope-Based Peptide Vaccine against the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): A Vaccine-informatics Approach 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.